Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;69(3):542-549.
doi: 10.1002/art.39971.

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Jorge A Zamora-Legoff  1 , Megan L Krause  1 , Cynthia S Crowson  1 , Jay H Ryu  1 , Eric L Matteson  1
Affiliations

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Jorge A Zamora-Legoff et al. Arthritis Rheumatol. 2017 Mar.

Abstract

Objective: Interstitial lung disease (ILD) is associated with substantial morbidity in rheumatoid arthritis (RA), but very little is known about its long-term progression. This study was undertaken to investigate the progression of pulmonary disease using a large single-center cohort of patients with RA-associated ILD.

Methods: Records of all patients with RA-associated ILD seen at Mayo Clinic between 1998 and 2014, with at least 4 weeks follow-up and at least 1 pulmonary function test, were identified and manually screened for study inclusion. Progression was defined as a diffusing capacity for carbon monoxide (DLco) <40% predicted (or patients whose illness was too advanced to undergo screening) or a forced vital capacity (FVC) <50% predicted. Time to progression was analyzed using the Kaplan-Meier method.

Results: Of the 167 patients included in the study, 81 (49%) were female, with a mean ± SD age of 67 ± 10 years at diagnosis of ILD. Median follow-up time from diagnosis of ILD was 3.3 years (range 0.01-14.8). One-third of the patients required supplemental oxygen, 40% developed DLco <40% predicted, and 22% developed FVC <50% predicted within 5 years after ILD diagnosis. Usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP) was a risk factor for DLco progression (hazard ratio 3.29 [95% confidence interval 1.28-8.41]). Lower DLco and FVC at baseline increased the risk for progression to DLco <40% predicted and FVC <50% predicted, and higher rates of change in the first 6 months also increased the risk of progression.

Conclusion: Progressive loss of pulmonary function is common in RA-associated ILD and is worse in patients with UIP than in those with NSIP. Predictors of progression in patients with RA-associated ILD may aid clinicians in identifying patients at highest risk for progression of ILD.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no relevant conflicts of interest to disclose

Figures

Figure 1
Figure 1
Estimated percentage of patients with diffusing capacity for carbon monoxide (DLCO) <40% (or too ill to perform the test) (solid line) and with forced vital capacity (FVC)<50% (dashed line) according to time since diagnosis of interstitial lung disease (ILD) in 167 patients with rheumatoid arthritis and ILD.
Figure 2
Figure 2
Estimated percentage of patients with diffusing capacity for carbon monoxide (DLCO) <40% (or too ill to perform the test) (upper panel) and with forced vital capacity (FVC) <50% (lower panel) according to time since diagnosis of interstitial lung disease (ILD) in 167 patients with rheumatoid arthritis and ILD subdivided by ILD type (solid line is usual interstitial pneumonia; dashed line is non-specific interstitial pneumonia).
See this image and copyright information in PMC

References

    1. Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33–6. - PubMed
    1. Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2013;65(8):1243–50. - PMC - PubMed
    1. Doyle JJ, Eliasson AH, Argyros GJ, Dennis GJ, Finger DR, Hurwitz KM, et al. Prevalence of pulmonary disorders in patients with newly diagnosed rheumatoid arthritis. Clin Rheumatol. 2000;19(3):217–21. - PubMed
    1. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91. - PMC - PubMed
    1. Travis WD, Costabel U, Hansell DM, King TE, Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48. - PMC - PubMed

Publication types